Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers.
Aged
CA-19-9 Antigen
/ blood
Carcinoma, Pancreatic Ductal
/ diagnostic imaging
Colonic Neoplasms
/ diagnostic imaging
Contrast Media
Gastrointestinal Stromal Tumors
/ diagnostic imaging
Humans
Incidental Findings
Male
Multidetector Computed Tomography
Pancreatic Neoplasms
/ diagnostic imaging
Sigmoid Neoplasms
/ diagnostic imaging
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
30
1
2020
Statut:
epublish
Résumé
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressive malignancy that exhibits an extremely poor prognosis, with most cases diagnosed at an advanced stage. To date, few reports have explored the natural history of PDAC, and the period leading up to the detection of PDAC as a tumor with contrast-enhanced computed tomography (CECT) remains unclear. Here, we report 3 PDAC cases diagnosed incidentally by repeating imaging examinations during observation of other organ cancers. CASE REPORT Two patients were undergoing postoperative follow-up for colorectal cancer; owing to the elevation of serum CA19-9 or dilatation of the main pancreatic duct, both cases were finally diagnosed with PDAC. Another patient was administered neoadjuvant chemotherapy for a gastrointestinal stromal tumor; the fluorodeoxyglucose uptake in the pancreas with fluorodeoxyglucose positron emission tomography for the treatment assessment led to the diagnosis of PDAC. All patients underwent frequent CECT for assessment of other diseases, and PDAC became visible with CECT within 3-4 months of the appearance of indirect findings of PDAC. CONCLUSIONS The period leading up to the detection of PDAC as a tumor with CECT was approximately 3-4 months. These cases suggest that additional imaging examinations should be performed when the indirect findings of PDAC are noted. This report adds value to the literature by elucidating the natural course of PDAC.
Identifiants
pubmed: 31335860
pii: 917197
doi: 10.12659/AJCR.917197
pmc: PMC6668584
doi:
Substances chimiques
CA-19-9 Antigen
0
Contrast Media
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1084Références
AJR Am J Roentgenol. 2004 Mar;182(3):619-23
pubmed: 14975959
Ann Intern Med. 2004 Nov 16;141(10):753-63
pubmed: 15545675
Endoscopy. 2005 Feb;37(2):146-53
pubmed: 15692930
Scand J Gastroenterol. 1992 Apr;27(4):317-25
pubmed: 1589710
Cancer. 1992 Feb 15;69(4):936-40
pubmed: 1735084
J Nucl Med. 2008 Sep;49(9):1408-13
pubmed: 18703604
Best Pract Res Clin Gastroenterol. 2010 Jun;24(3):349-58
pubmed: 20510834
World J Gastroenterol. 2011 Jan 14;17(2):231-5
pubmed: 21245997
Pancreas. 2011 Apr;40(3):364-70
pubmed: 21289527
Radiology. 2011 Jun;259(3):757-66
pubmed: 21436084
Dig Endosc. 2011 May;23 Suppl 1:22-5
pubmed: 21535195
Cancer. 2012 Mar 1;118(5):1244-51
pubmed: 21887676
Ann Oncol. 2012 Jul;23(7):1880-8
pubmed: 22104574
Clin Gastroenterol Hepatol. 2013 Jun;11(6):712-8
pubmed: 23353642
Endoscopy. 2014 Jan;46(1):22-9
pubmed: 24218310
Med Oncol. 2016 Jul;33(7):61
pubmed: 27225938
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
J Gastrointest Cancer. 2017 Jun;48(2):164-169
pubmed: 27699624
Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):149-156
pubmed: 27937041
United European Gastroenterol J. 2018 Jul;6(6):888-894
pubmed: 30023066
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593